Galapagos Nv

Abbvie S.a.r.l.

Abbvie Inc.

Abbvie Overseas Sarl

Anurupa Shrestha

Philip R Kym

Gregory A Gfesser

Marlon D Cowart

Xueqing Wang

Jianguo Ji

Christel Jeanne Marie Menet

Nicolas Desroy

Steven Emiel Van Der Plas

Sachin V Patel

Brian S Brown

Luke Jonathan Alvey

Jean-Michel Lefrancois

Christopher Gaëtan Housseman

Oscar Mammoliti

Xavier Marie Bock

Romain Luc Marie Gosmini

Gregory John Robert Newsome

Béranger Duthion

Pieter Isabelle Roger Claes

Rhalid Akkari

Elsa De Lemos

Koen Karel Jansen

Adeline Marie Elise Palisse

Elizabeth C Swift

Nuria Merayo Merayo

Eric A Voight

Ann De Blieck

Matthieu Rafaël Pizzonero

Arthur Gomtsyan

Jerome F Daanen

Michael E Kort

Kevin R Woller

Mathieu Rafaël Pizzonero

Rolf Wagner

Michael J Dart

John T Randolph

David A DeGoey

Allan C Krueger

Sridhar Peddi

Yi-Yin Ku

Irene I Drizin

Huaqing Liu

Tongmei Li

Derek W Nelson

Tammie K Jinkerson

Hui-Ju J Chen

Ryan G Keddy

Howard Robin Heyman

Kathleen Mortell

Christopher C Marvin

John Hartung

Vikram Kalthod

Geoff T Halvorsen

Katja Conrath

Chris Tse

Jaclyn Chau

Nathan Ide

Douglas Cyr

Gert Jules Hector De Wilde

Steven R Martinez

The present invention provides for compounds of formula (I) wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.

Compounds for treatment of cystic fibrosis

The present invention features compounds effective in inhibiting active against Hepatitis C virus ('HCV') polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

The present invention provides for compounds of formula (I) wherein R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

[object Object]

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, R, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Growing community of inventors

Vernon Hills, IL, United States of America

Anurupa Shrestha